Bowmark Capital, a mid-market private equity firm, has agreed to sell CARE Fertility (CARE), a UK fertility clinic group for IVF treatment, to Silverfleet Capital.
Established in 1997, CARE operates nine full-service fertility clinics supported by a network of 13 satellite facilities, providing extensive coverage across the UK and Republic of Ireland. Since its formation, CARE has aided the conception of over 30,000 babies, and its success rates are amongst the highest in the UK. With an extensive R&D capability, CARE has become one of the world’s leading providers of fertility treatment, genetic diagnosis and screening techniques, and associated fertility preservation procedures. Its clinics offer the most advanced and effective procedures available, some of which were developed through the company’s own pioneering research.
Under Bowmark’s ownership, CARE has significantly expanded its operations, adding clinics in London, Tunbridge Wells, Bath, Birmingham and Dublin, through the development and acquisition of new sites, as well as investing in its existing facilities. Whilst undergoing this expansion, the company has remained at the forefront of new clinical technology, including developing the time lapse embryo imaging technique, CAREmaps, which can significantly increase patient success rates.
Simon Fishel, founder of CARE, says: “With Bowmark’s help, CARE has grown in scale but never lost sight of the importance of delivering the best outcomes for our patients. Much has been achieved since the birth of the first IVF baby in 1978, but so much potential remains to further our understanding of infertility and we look forward to embarking on the next phase.”
CARE’s chief executive, David Burford, adds: “With Bowmark’s support, we have made excellent progress over recent years expanding our clinic footprint, investing in our operations and continuing to improve our success rates.”
David Torbet, Bowmark partner, says: “It has been a privilege to be involved in CARE and to work with the management team to grow the business. CARE has always led the fertility market in seeking to give patients the very best chance of having a baby, and we wish the company continued success under its new owners.”
Bowmark Capital was advised by KPMG, and CARE’s management team was advised by Deloitte.